Teva Pharmaceutical Industries' (TEVA) share price dropped close to 45% last year, and the company faces a Department of Justice investigation into alleged price fixing, along with five other pharmaceutical companies.
The DoJ investigation, which was announced Dec. 5, relates to past conduct irregularities in countries like Ukraine, Russia, and Mexico, but did not involve Teva's U.S. operations. The case also involves Mylan, Heritage Pharmaceuticals, Aurobindo Pharma, Citron Pharma and Mayne Pharma.
Last month, Teva settled a separate case with the Securities and Exchange Commission by agreeing to pay $519 million. The SEC alleged that Teva gained an unfair market advantage by paying bribes to officials in Russia, the Ukraine and Mexico.